Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.58

+0.9%

Dec 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4845)	10/22/2001 8:31:55 PM
From: Miljenko Zuanic	Read Replies (1) of 52153

<<Apples to Oranges There are some important differences between Iressa and C225 that make direct comparisons difficult. Iressa is a small-molecule drug that works inside of cancer cells; C225 is a monoclonal antibody that interacts with proteins on the outside of cells. Biotech observers are split over which approach will work better, and the drugs haven't been tested enough to provide definitive proof either way.>> When will this high paid analyst learn to do mindful DD before...? One of several Iressa abstracts: <<The tyrosine kinase inhibitor ZD1839 (‘Iressa’) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumors>> and from NSCLC abstract: <<Patients were not selected by tumor EGFR status. >> If this is true, and if one count that EGFr hetero-dimerize with HER-2, than it is question does C225 (and ABX-EGF)bind strongly to this hetero-complex type? So far, monotherapy results in NSCLC (also valid for OSIP drug), and ovarian and breast cancer, suggest that Iressa is active toward combination of the receptors. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next